טוען...
Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
INTRODUCTION: Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD). The recommended dose of the dipeptidyl peptidase-4 inhibitor saxagliptin is 2.5 mg in patients with moderate or severe renal impairment (creatinine clearance ≤50 mL/min). In this post hoc analysis, we assessed...
שמור ב:
| הוצא לאור ב: | Diabetes Ther |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer Healthcare
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5014790/ https://ncbi.nlm.nih.gov/pubmed/27402391 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-016-0184-9 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|